CALIXAR will attend the 7th Annual Immuno-Oncology Innovation Forum on May 18 – 20, 2021

May 12, 2021

CALIXAR team will be present at the online 7th Annual Immuno-Oncology Innovation Forum, from May 18 to May 20, 2021 to meet and share with key-decision makers about commercial and scientific opportunities for investing in challenging therapeutic targets.

CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters …). This digital event will be a great opportunity to present CALIXAR’s proprietary technologies and know-how to make the best pharmaceutical targets for the development of innovative drugs and antibodies.

The company works currently on a new pipeline of highly druggable membrane protein targets and native antigens. The meetings of this event could allow the identification of therapeutic targets of high relevance for the pharmaceutical and biotechnological market today.

About the 7th Annual Immuno-Oncology Innovation Forum

The 7th Annual IOIF program will be spread throughout 3 days. Featuring more than 14 hours of keynotes, high-level speeches, panel discussions and spotlight showcases by leading corporates. The event brings together leaders from pharma and biotech as well as cancer research institutes, patient advocacy groups, early and late-stage investors, CMOs and CROs.

For more information and meet us: 7th Annual Immuno-Oncology Innovation Forum

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.